...
首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression.
【24h】

The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression.

机译:帕罗西汀和替丁汀对抑郁症患者外周生化指标的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Depression is related to the alterations of the central serotonergic system and some antidepressants achieve their therapeutic effects through alteration of serotonin (5-HT) (re)uptake. Peripheral biochemical markers, platelet and serum 5-HT concentrations, platelet monoamine oxidase (MAO) activity, plasma levels of cortisol and prolactin (PRL), were investigated in patients with major depression before and after 4 weeks of treatment with paroxetine (an inhibitor of 5-HT uptake) or tianeptine (a stimulator of 5-HT uptake). Study was open, single center and included female depressed patients, 21 treated with tianeptine (37.5 mg/day) and 15 treated with paroxetine (20 mg/day), and 11 drug-free healthy women (controls). Before treatment, depressed patients as a group had significantly higher serum 5-HT and cortisol concentrations than healthy controls. There were no differences in the other biochemical markers. Response to antidepressant treatment was estimated according to the 50% fall in the initial scores of Hamilton Depression Rating Scale (HAMD) after 4 weeks of treatment. Good therapeutic response was observed in 47% and 45% patients treated with paroxetine and tianeptine, respectively. Paroxetine treatment induced significant decrease in platelet 5-HT concentrations in both responders and nonresponders, while no alterations in platelet 5-HT values were found in tianeptine-treated patients. There was a subgroup of depressed patients in paroxetine-treated group with high pretreatment platelet 5-HT concentration and later poor therapeutic response to paroxetine treatment. Serum 5-HT values, platelet MAO activity or plasma cortisol or PRL levels were unchanged after both treatments. The results suggest that pretreatment platelet 5-HT levels, but not other peripheral biochemical markers, might predict therapeutic outcome at least in paroxetine-treated patients.
机译:抑郁症与中枢5-羟色胺能系统的改变有关,一些抗抑郁药通过改变5-羟色胺(5-HT)(再摄取)来达到治疗作用。在患有严重抑郁症的患者中,在用帕罗西汀(帕罗西汀的一种抑制剂5-HT摄取量)或噻庚汀(5-HT摄取刺激物)。该研究是开放的,单中心的,包括女性抑郁症患者,21例使用噻庚汀(37.5 mg /天)和15例使用帕罗西汀(20 mg /天)的患者以及11例无毒品的健康女性(对照组)。治疗前,抑郁症患者的一组血清5-HT和皮质醇浓度明显高于健康对照组。其他生化标记没有差异。根据治疗4周后汉密尔顿抑郁量表(HAMD)的初始评分下降50%来估计对抗抑郁药治疗的反应。分别用帕罗西汀和替丁汀治疗的患者中有47%和45%的患者观察到良好的治疗反应。帕罗西汀治疗在有反应者和无反应者中均引起血小板5-HT浓度的显着降低,而在经天肽治疗的患者中未发现血小板5-HT值发生改变。帕罗西汀治疗组中有一个抑郁症患者亚组,其治疗前血小板5-HT浓度较高,但对帕罗西汀治疗的治疗反应较差。两种治疗后,血清5-HT值,血小板MAO活性或血浆皮质醇或PRL水平均未改变。结果表明,至少在帕罗西汀治疗的患者中,治疗前的血小板5-HT水平(而非其他外周生化指标)可能预示了治疗结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号